Retatrutide 10 mg Vial Price: $10.00/mg and How to Compare
A tracked 10 mg retatrutide vial at $100 works out to $10.00/mg; the 20 mg at $195 is $9.75/mg. Normalize vendor listings before comparing.
- retatrutide
- pricing
- vendor comparison
- cost per mg
A 10 mg retatrutide vial in the tracked catalog lists at $100 as of September 2026, which is $100 ÷ 10 = $10.00 per mg. The 20 mg listing at $195 is $195 ÷ 20 = $9.75 per mg, a 2.5% gap. Any other retatrutide 10 mg vial price becomes comparable only after you divide it by labeled peptide mass and then load shipping and any order minimum on top, because a lower sticker on a smaller or differently filled vial loses on cost per mg more often than it wins.
Snapshot dates decide whether a comparison is usable at all. A retatrutide vendor comparison carrying a 2025 date describes listings that have been repriced since; every dollar figure on this page is tied to the September 2026 catalog pull and nothing else.
What is a 10 mg retatrutide vial worth per mg?
Cost per mg is list price divided by labeled mg, and it is the only figure that survives a change of vial format.
| Format | List price (USD) | Cost per mg (USD) | Cost of 20 mg (USD) |
|---|---|---|---|
| 10 mg vial | 100.00 | 10.00 | 200.00 (2 vials) |
| 20 mg vial | 195.00 | 9.75 | 195.00 (1 vial) |
Caption: per-mg cost of the two tracked retatrutide formats, computed as list price ÷ labeled mg from catalog prices as of September 2026.
The $5.00 difference in the last column is the entire structural advantage the larger vial holds at 20 mg, and it is small enough that a per-vial shipping or handling charge reverses it. A vendor quoting flat-rate shipping and a vendor quoting per-vial shipping produce different rankings from identical sticker prices, which is the first thing to check in a supplier-by-supplier price index.
How many 10 mg vials does a 36-week dose arm consume?
The phase 2 body-composition substudy randomly assigned adults with type 2 diabetes to once-weekly subcutaneous placebo, dulaglutide 1.5 mg, or retatrutide at 0.5 mg, 4 mg, 8 mg, or 12 mg, with 189 participants enrolled into the substudy and percent change in total fat mass at week 36 as the prespecified primary endpoint, per the phase 2 retatrutide body-composition substudy. Those four dose levels give a scale for reading vial counts, since the 8 mg pooled arm showed a 26.1% (SE 2.5%) reduction in total fat mass at week 36 and the 12 mg arm 23.2% (SE 3.0%) in the same report.
Because the 8 mg and 12 mg arms started from 2 mg or 4 mg initial doses and titrated upward in that same trial, multiplying a target weekly dose by 36 weeks returns a ceiling on total exposure rather than the amount actually administered.
| Weekly dose (mg) | Total mg, 36 weeks | 10 mg vials (cost USD) | 20 mg vials (cost USD) | Cheaper format |
|---|---|---|---|---|
| 0.5 | 18 | 2 (200.00) | 1 (195.00) | 20 mg by 5.00 |
| 4 | 144 | 15 (1,500.00) | 8 (1,560.00) | 10 mg by 60.00 |
| 8 | 288 | 29 (2,900.00) | 15 (2,925.00) | 10 mg by 25.00 |
| 12 | 432 | 44 (4,400.00) | 22 (4,290.00) | 20 mg by 110.00 |
Caption: vials required to cover each phase 2 dose arm across the substudy’s 36-week horizon, computed as weekly dose × 36 ÷ vial mg, rounded up to whole vials, then multiplied by tracked catalog prices ($100 per 10 mg, $195 per 20 mg, as of September 2026). Dose arms and the 36-week endpoint come from the phase 2 substudy record cited above. These are research-use listings, and the arithmetic compares catalog quantities, not protocols.
Two of the four rows go to the format with the worse per-mg price. At 144 mg, fifteen 10 mg vials buy 150 mg for $1,500.00 while eight 20 mg vials buy 160 mg for $1,560.00: the larger format forces 160 − 144 = 16 mg of surplus against 150 − 144 = 6 mg, and 10 mg of extra peptide at $9.75 costs more than the 2.5% per-mg saving returns. Granularity beats per-mg price whenever the quantity you need is not a clean multiple of 20.
Per-dose arithmetic runs the same way. At $10.00/mg a 4 mg quantity costs 4 × 10.00 = $40.00 and an 8 mg quantity costs $80.00, so one 10 mg vial covers 10 ÷ 4 = 2.5 four-mg doses but only 10 ÷ 12 = 0.83 of a 12 mg dose. The step from vial price to per-dose cost is where partial-vial waste shows up.
What price does a rival 10 mg listing have to beat?
Work backward from the per-mg benchmark. To match $9.75/mg, a 10 mg vial has to sell at 9.75 × 10 = $97.50. The required cut from $100.00 is (100 − 97.50) ÷ 100 = 0.025, or 2.5%.
That leaves a dead band worth naming. A competing 10 mg listing priced between $97.50 and $100.00 beats the tracked 10 mg benchmark and still loses to the 20 mg format on cost per mg, so a vendor advertising a discount inside that window has undercut one number and not the other. Below $97.50 the 10 mg listing wins on both, and the comparison is over before shipping is added.
The dead band moves whenever the larger vial is itself discounted. A 20 mg vial at 10% off lists at 195 × 0.9 = $175.50, or $175.50 ÷ 20 = $8.775/mg, which puts the 10 mg break-even at 8.775 × 10 = $87.75 and the required cut at (100 − 87.75) ÷ 100 = 12.25%.
Which listing fields make two 10 mg prices non-comparable?
Six fields have to match before two retatrutide 10 mg vial prices can sit in the same column:
- Labeled peptide mass versus gross fill weight. A per-mg price computed from total powder weight uses a different denominator than one computed from peptide content, and no arithmetic reconciles them after the fact.
- Stated overfill. A vendor claiming surplus fill is quoting against a number that does not appear on the label; treat the labeled mass as the denominator unless the certificate of analysis states the assayed content.
- Shipping basis. Per-vial fees scale with unit count, flat fees do not, and the gap between the two formats at 20 mg is only $5.00.
- What the minimum order counts. Vials, kits, or dollars. A three-kit minimum on a two-vial kit is a six-vial commitment.
- Payment surcharge. A card-versus-transfer differential applied at checkout changes the effective per-mg figure after the comparison table was built.
- Snapshot date. Any per-mg number carries the date its listing was pulled, and a 2025 comparison table is a historical record rather than a quote.
Testing depth belongs in the same audit, because purity and identity documentation is the variable that separates two listings at the same price. The relationship between documentation depth and listed price is where a cheap 10 mg vial usually explains itself, and the smaller formats compound the effect, as the 10 mg versus 5 mg breakdown shows.
Is there a published list price to compare vendors against?
No. Retatrutide remains investigational, which is why access outside trials runs through pre-approval single-patient expanded access for adults with a BMI of at least 35 kg/m² and at least two serious or life-threatening obesity-related complications who are refractory to the best approved therapy, per the retatrutide expanded access record. The registrational program is still open: four phase 3 randomized, double-blind studies of weekly subcutaneous retatrutide against placebo in over 5,800 participants, with percent change in body weight as the weight-management primary endpoint, per the TRIUMPH trial design paper.
Approved GLP-1 receptor agonists give the nearest anchor for what an eventual list price does to cumulative cost. A cost analysis comparing 2023 US national retail prices against inflation-adjusted 2015 surgical estimates found cumulative medication cost for Saxenda and Wegovy exceeds the cost of Roux-en-Y gastric bypass in under a year and sleeve gastrectomy within nine months, while the cheapest option assessed, Byetta, crosses at roughly 1.5 years, per the GLP-1 versus bariatric surgery break-even analysis. That paper reports break-even durations rather than per-mg figures, so it fixes the time axis of a cost comparison and leaves the price axis to the listings themselves.
Before converting any vendor’s 10 mg price to a per-mg number, ask for labeled peptide mass and gross fill weight as two separate figures and use the first as the denominator.